Nursing Elites

1. Which of the following is the antidote for lead poisoning?

• A. Naloxone
• B. Nitrite
• C. CaEDTA
• D. Dialysis

Correct answer: C

Rationale: Calcium disodium ethylenediaminetetraacetic acid (CaEDTA) is the antidote for lead poisoning. CaEDTA works by chelating lead, forming a complex that is then excreted in the urine. It is used in chelation therapy to treat lead poisoning by reducing lead levels in the body.

2. What is the antidote for Heparin?

• A. Atropine
• B. Protamine sulfate
• C. Calcium carbonate
• D. Ferrous sulfate

Correct answer: B

Rationale: Protamine sulfate is the specific antidote used to reverse the effects of Heparin by binding to heparin and neutralizing its anticoagulant properties. It is crucial to administer Protamine sulfate promptly in cases of Heparin overdose or when immediate reversal of Heparin's effects is required to prevent bleeding complications. Atropine is not the antidote for Heparin; it is commonly used for treating bradycardia. Calcium carbonate is used to treat conditions like acid indigestion, heartburn, or calcium deficiency. Ferrous sulfate is a form of iron supplement used to treat or prevent iron deficiency anemia. None of these alternatives are antidotes for Heparin.

3. When educating a client with early Parkinson's disease about pramipexole, what adverse effect should the nurse advise the client to monitor for?

• A. Hallucinations
• B. Increased salivation
• C. Diarrhea
• D. Discoloration of urine

Correct answer: A

Rationale: The correct answer is A: Hallucinations. Pramipexole can lead to hallucinations, especially within 9 months of starting the medication, and may necessitate discontinuation. Hallucinations are a serious adverse effect that the client should be aware of and report promptly to their healthcare provider for evaluation and management. Increased salivation (choice B), diarrhea (choice C), and discoloration of urine (choice D) are not common adverse effects associated with pramipexole and are not typically emphasized in client education for this medication.

4. A healthcare provider is reviewing the health history of a client who is starting therapy with tamoxifen. The healthcare provider should recognize that tamoxifen is contraindicated in which of the following clients?

• A. A client with a history of deep-vein thrombosis
• B. A client with a history of migraine headaches
• C. A client with a history of hypertension
• D. A client with a history of anemia

Correct answer: A

Rationale: Tamoxifen is contraindicated in clients with a history of thromboembolic events, such as deep-vein thrombosis, due to the increased risk of blood clots. The estrogenic effects of tamoxifen can further increase the risk of thromboembolic events, making it unsafe for individuals with a history of deep-vein thrombosis. Choice B (migraine headaches), Choice C (hypertension), and Choice D (anemia) are not contraindications for tamoxifen therapy. Migraine headaches, hypertension, and anemia do not pose the same risk of adverse effects related to blood clot formation as deep-vein thrombosis does.

5. When a client is taking Somatropin to stimulate growth, what should the healthcare provider monitor the client's urine for?

• A. Bilirubin
• B. Protein
• C. Potassium
• D. Calcium

Correct answer: D

Rationale: When a client is taking Somatropin to stimulate growth, monitoring urine for calcium is essential. Somatropin can lead to increased calcium levels in the urine, potentially increasing the risk of renal calculi formation. Therefore, assessing for calcium in the urine helps in early detection and prevention of this complication. Monitoring for bilirubin, protein, or potassium in the urine is not directly related to the effects of Somatropin and would not provide relevant information in this context.

Similar Questions